El papel de la ceramida y el metabolismo de los esfingolipidos en la terapia del cáncer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.El metabolismo de los esfingolipidos, crucial en el cáncer, incluye lípidos clave como el esfingosina-1-fosfato (S1P) y la ceramida. Las terapias dirigidas a la relación S1P/ceramida promotora del cáncer son prometedoras para el tratamiento del cáncer.
Área De La Ciencia
- La bioquímica
- Biología celular
- En el campo de la oncología
Sus Antecedentes
- Los esfingolipidos son lípidos bioactivos vitales que regulan las funciones celulares, incluida la señalización, la composición de la membrana y el destino celular.
- El metabolismo esfingolipídico desregulado está implicado en el desarrollo y la progresión del cáncer.
- El equilibrio entre la esfingosina-1-fosfato (S1P) y la ceramida influye en la supervivencia y muerte de las células cancerosas.
Objetivo Del Estudio
- Revisar el papel del metabolismo de los esfingolipidos en el cáncer.
- Resumir las estrategias terapéuticas actuales y emergentes dirigidas al metabolismo de los esfingolipidos para el tratamiento del cáncer.
Principales Métodos
- Revisión de la literatura sobre el metabolismo de los esfingolipidos y el cáncer.
- Análisis de las funciones de los esfingolipidos clave, S1P y ceramida, en la biología celular del cáncer.
- Examen de los enfoques terapéuticos que modulan el equilibrio ceramida/S1P.
Principales Resultados
- Las células cancerosas a menudo exhiben una relación elevada de S1P a ceramida, lo que promueve la supervivencia.
- La ceramida actúa como un lípido pro-muerte, induciendo la apoptosis, la detención del ciclo celular y la mitofagia.
- La señalización S1P generalmente promueve la supervivencia de las células cancerosas.
Conclusiones
- Dirigirse al metabolismo de los esfingolipidos, particularmente a la relación ceramida/S1P, es una estrategia terapéutica prometedora en oncología.
- Tanto las nuevas terapias como los medicamentos reutilizados pueden modular el metabolismo de los esfingolipidos para el tratamiento del cáncer.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...